Evidence map›Paper›PMID 30850323›Full record

ArticleEuropean journal of cancer (Oxford, England : 1990)2019

Prostate cancer incidence and mortality among men using statins and non-statin lipid-lowering medications.

Maria I Van Rompay, Keith R Solomon, J Curtis Nickel, Gayatri Ranganathan, Philip W Kantoff, John B McKinlay

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of cancer (Oxford, England : 1990), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 2 pooled it
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 2 syntheses or guidelines pooled it, 48 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Review
  5. Article
  6. Article
  7. Article
  8. Residual Traditional Risk in Non-Traditional Atherosclerotic Diseases.International journal of molecular sciences · 2025
    Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Targeting lipid metabolism in metastatic prostate cancer.Therapeutic advances in medical oncology · 2023
    Review
  15. Review
  16. Review
  17. Article
  18. Article
  19. Review
  20. The Association of Prediagnostic Statin Use with Aggressive Prostate Cancer from the Multiethnic Cohort Study.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2022
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 2 countries.

Maria I Van RompayHealthCore-NERI, 480 Pleasant Street, Watertown, MA 02472, USA. Electronic address: mvanrompay@neriscience.com.
Keith R SolomonDepartment of Orthopaedic Surgery, Harvard Medical School, Boston Children's Hospital, Boston, MA 02115, USA; Department of Urology, Boston Children's Hospital, Boston, MA 02115, USA. Electronic address: drmungo@yahoo.com.
J Curtis NickelDepartment of Urology, Queen's University, Kingston, ON, Canada. Electronic address: jcn@queensu.ca.
Gayatri RanganathanHealthCore-NERI, 480 Pleasant Street, Watertown, MA 02472, USA. Electronic address: GRanganathan@neriscience.com.
Philip W KantoffDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA. Electronic address: kantoff@mskcc.org.
John B McKinlayHealthCore-NERI, 480 Pleasant Street, Watertown, MA 02472, USA; Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA. Electronic address: jandsmckinlay@gmail.com.
New England Research Institutes · USBoston Children's Hospital · USHarvard University · USMemorial Sloan Kettering Cancer Center · USQueen's University · CA

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Chemoprevention of Prostate CancerR01AG038453 · NIA · NEW ENGLAND RESEARCH INSTITUTES, INC. · PI VAN ROMPAY, MARIA IRENE · 2011 to 2014
$623k
NCI NIH HHS P30 CA008748NIA NIH HHS R01 AG038453
6 · The paper itself

Abstract

backgroundStatins have demonstrated protection against aggressive/late-stage and/or lethal prostate cancer (PC), but prior studies are limited by small populations, short follow-up and unequal health-care access. Research has not demonstrated that non-statin lipid-lowering medications (NSLLMs) provide a similar benefit, which would support a cholesterol-based mechanism. We sought to rigorously test the hypothesis that cholesterol-lowering drugs affect PC incidence and severity.

methodsA retrospective cohort study was conducted by abstracting prescription and health service records for 249,986 Saskatchewan men aged ≥40 years between January 1, 1990 and December 31, 2014 and comparing first-time statin and NSLLM users with age-matched non-users and glaucoma medication (GM) users for PC incidence, metastases at diagnosis and PC mortality using Cox proportional hazards regression.

resultsIn comparing statin users to non-users, a weak association was detected with increased PC incidence (hazard ratio [HR] 1.07, 95% confidence interval [CI]: 1.02-1.12) that disappeared when compared with GM users. Substantial protective associations were observed between statin use and metastatic PC and PC mortality (HRs 0.69, 95% CI: 0.61-0.79 and 0.73, 95% CI: 0.66-0.81, respectively), which were stronger when compared with GM use (HRs 0.52, 95% CI: 0.40-0.68 and 0.51, 95% CI: 0.41-0.63, respectively). Similar associations were found for NSLLM versus GM for metastatic PC (HR 0.57, 95% CI: 0.41-0.79) and PC mortality (HR 0.66, 95% CI: 0.51-0.85).

conclusionsOur analyses provide one of the more comprehensive findings to date that statins may reduce risk of metastatic PC and PC mortality, and the first to demonstrate that NSLLM have similar effects, supporting a cholesterol-based mechanism.

Indexed as

HumansHydroxymethylglutaryl-CoA Reductase InhibitorsIncidenceLipid MetabolismMaleMiddle AgedProportional Hazards ModelsProstatic NeoplasmsRetrospective StudiesHydroxymethylglutaryl-CoA Reductase InhibitorsHydroxymethylglutaryl-CoA reductase inhibitorsPharmacoepidemiologyProstatic neoplasms

Identifiers

PMID30850323
PMCPMC6501826
OpenAlexW2922245160

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.